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animal science; Ching Chang; Gerard J. Hickey, director, 
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Summary and Implications 
 A dose-dependent response of GH plasma concentration 
to icv injection of 3, 10 and 30 µg/kg BW of the GH-
secretagogue, L-692,585 (585) was established in Yorkshire 
barrows (40-45 kg BW).  Icv administration of CRH at 150 
µg/kg BW did not raise basal GH concentration compared 
with saline treatment, and icv injection of 585 at three dosages 
did not significantly alter cortisol plasma concentration.  Icv 
injection of SRIF dose-dependently decreased GH plasma 
concentration, whereas icv treatment of SRIF + 585 dose-
dependently increased GH concentration but at peak levels 
less than seen with 585 alone.  Icv injection of pGAL 
modestly increased GH peak concentration, whereas when 
given in combination with 585 acutely raised GH plasma 
concentration.  GH plasma concentration remained at basal 
levels after icv injection of pNPY, whereas when given in 
combination with 585 modestly elevated GH concentration at 
peak levels less than seen with 585 alone.  The administration 
of 585 icv elicited a slower and less robust GH response than 
that following iv 585; desensitization of the GH response 
occurred following repeated icv 585 but not repeated iv 585.  
These findings demonstrate that 585, administered iv or icv, is 
a potent GH-secretagogue and confirm its central role in the 
pig. 
 
Introduction 
 Growth hormone (GH) is released in a circadian, 
pulsatile fashion controlled by two hypothalamic hormones, 
GH-releasing hormone (GHRH) induces whereas 
somatostatin (SRIF) inhibits GH release. The development 
of the novel nonpeptidyl growth hormone secretagogue, L-
692,429 and analogs, with potent GH-releasing activity both 
in vivo and in vitro and the natural ligand, ghrelin, provides 
a means to understand biological mechanisms of GH 
release. 
 L-692,429, a substituted benzolactam, acts in a manner 
identical to the peptidyl GH secretagogue, GHRP-6, but 
distinct from that of the endogenous GHRH. L-692,585 
(585) is approximately 5- to 30-fold more potent based on in 
vitro and in vivo studies, and with no detectable change in 
receptor specificity.  Our preliminary experiment showed 
that 585 has a direct but limited action at the level of the 
pituitary gland, and that an intact hypophyseal stalk is 
required for a maximal GH and cortisol response. 
 We selected pigs as the species for this study because 
their responsiveness and specificity to this class of 
secretagogues closely resembles that of the human. 
Intracerebroventricular (icv) stainless steel cannulas were 
placed surgically to elucidate the nonpeptidyl GH 
secretagogues’ effect on central regulation of GH secretion 
in immature male castrates. The pharmacological actions on 
central mechanisms by which 585 controls GH release was 
determined by a) dose-dependent effects of icv administered 
585, b) by a switchback design of icv and iv administered 
drug and c) by icv administration of somatostatin, porcine 
neuropeptide Y (pNPY) and porcine galanin (pGAL) alone 
or in combination with 585. 
 
Materials and Methods 
Animals 
 Fourteen Yorkshire castrated males, weighing 40-45 kg, 
were used in this study. Animals were housed in individual 
stainless steel metabolism crates for the duration of the study, 
and a corn and soybean meal-based diet was available ad 
libitum. 
 
Surgical Procedures 
 Pigs were anesthetized with an ear vein injection of 
sodium thiopental (0.14 mg/kg BW, Pentothal, Abbott 
Laboratories, North Chicago, IL, USA) for endotracheal 
intubation and maintained on a closed-circuit system of 
halothane (2-5 %; Ayerst Laboratories, Rouses Point, NY, 
USA) and oxygen (300 cc/min) for the duration of surgery. An 
external jugular vein was surgically exposed, and a catheter 
(id. 1.27 mm; od 2.29 mm; Tygon microbore tubing, Fisher 
Scientific, Pittsburgh, PA, USA) directed toward the cranial 
vena cava was inserted and sutured in place. The catheter was 
directed sc to the dorsal neck region and exteriorized between 
the scapulae for repeated blood sample collections. After 3 
days, the animal’s head was oriented in a large animal 
stereotaxic instrument (David Kopf Instruments, Tujunga, CA, 
USA) so that the plane formed by the frontal and parietal 
bones was parallel to the instrument tabletop. An 18-gauge 
stainless steel cannula was placed in the left lateral-cerebral 
ventricle according to predetermined coordinates (anterior-
posterior, +14.0 mm; lateral, 6.0 mm to the bregma; 
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horizontal, 18.0 mm to the dura mater). Two stainless steel 
screws and cranioplastic cement (Plastics One, Inc., Roanoke, 
VA, USA) secured the cannula. A backflow of cerebrospinal 
fluid indicated that the cannula was icv. 
 
Test Compound and Method of Administration 
 L-692,585 was dissolved in saline for iv and icv 
administration. Solutions were prepared at the beginning of 
each trial, so that solubilized 585 was not stored longer than 1 
day. L-692,585 or vehicle was administered icv in 150 μl 
solution and followed by 120 μl vehicle to fill cannula dead 
space. For iv injection 300 μl of 585 or saline solution was 
followed by 2 ml vehicle (saline). To evaluate the integrity of 
the pituitary gland and as a positive control, the animals were 
challenged with corticotropin-releasing hormone (CRH; 150 
μg) and assayed for GH and cortisol. pCRH (American 
Peptide Co., Inc. Sunnyvale, CA, USA) was dissolved in 
sterile saline (0.9% NaCl) and stored frozen (-80 C) in 150-μl 
aliquots. Peptide hormone solutions were prepared at the 
beginning of each trial, so that solubilized CRH was not stored 
longer than 1 week. CRH or vehicle was administered icv in 
150 μl solution. This was followed by 120 μl saline to account 
for dead space in the catheter. 
 Somatostatin 1-14 (SRIF), porcine galanin (pGAL) and 
porcine neuropeptide Y (pNPY) (American Peptide Co., Inc.) 
were dissolved in sterile saline (0.9% NaCl) and stored frozen 
( 80  C). L-692,585 was dissolved in saline for icv 
administration. Peptide hormone and 585 solutions were 
prepared at the beginning of each trial so that solubilized 
peptide hormone and 585 were not stored longer than 1 day.  
Peptide hormone solution (SRIF, pGAL, pNPY) with or 
without 585 or vehicle was administered icv in 150 l solution 
and followed by 120 l vehicle to fill cannula dead space. 
 
Blood Samples 
 Blood (5 ml) was collected via an indwelling jugular 
cannula into heparinized tubes at each sampling. Samples were 
centrifuged, 1,500 × g within 2 h, and plasma was harvested 
and stored at –20  C until hormone assay. 
 
Hormone Assays 
 A homologous porcine GH RIA was developed utilizing 
reagents supplied by Dr. A F Parlow, Pituitary Hormone and 
Antisera Center, Harbor-UCLA Medical Center, Torrance, 
CA, USA (porcine GH [pGH] for iodination and standards, 
USDA-I-1; anti-pGH, AFP10318545). Sensitivity of the assay 
was 0.9 ng/ml. Intra- and inter-assay variations were 2.9 and 
15.6%, respectively. 
 Plasma cortisol concentrations were determined by a 
double-antibody RIA similar to that described previously. 
Plasma cortisol concentrations were quantified in duplicate 50-
μl aliquots through the use of a solid-phase 125I-RIA 
nonextraction technique. To validate the assay, known 
amounts of cortisol were added to charcoal-stripped cortisol-
free plasma as follows: 0.25, 0.5, 1.0, 2.5, and 5.0 ng/tube in 
quadruplicate. The plasma blank values were assayed and 
values were subtracted from those in tubes with known 
amounts of cortisol. Sensitivity of the assay was 0.92 ng/ml, 
whereas intra- and inter-assay coefficients of variation were 
11.2% and 2.5%, respectively. 
 
Experimental Protocol 
Dose-response effect of L-692,585 icv injection on GH and 
cortisol secretion. 
 Four pigs were used to determine the central dose 
dependent effects of 585 and CRH on GH and cortisol 
secretion. Saline or 585 at three dose levels (3, 10, 30 μg/kg 
BW) were administered by icv injections. Blood was collected 
at - 40, -20 (pretreatment), 0, 10, 20, 30, 40, 60, 80, 100, 120, 
and 140 min (post-treatment). 
 
Switchback study of L-692,585 iv and icv injection on GH 
secretion. 
 L-692,585 at 30 μg/kg BW was administered to animals 
according to a switchback design outlined in Figure 1. Blood 
was collected as described previously. 
 
SRIF with and without L-692,585 icv injection on GH 
secretion. 
 Doses of SRIF (2, 8 g/kg BW) with and without 585 (30 
g/kg BW), 585 alone or saline was administered by icv 
injections. 
 
pNPY and pGAL with and without L-692,585 icv injection on 
GH secretion. 
 
 pNPY or pGAL (4 g/kg BW) with and without 585 (30 
g/kg BW) was administered by icv injections. 
 
Statistical Analysis 
 Mean pretreatment GH and cortisol concentration as well 
as post treatment peak GH and cortisol concentration were 
obtained for each animal. Peak hormone level and peak 
occurring time were used to characterize hormone response 
profile of individual pigs. Data are expressed as the mean ± 
SE. All data were subjected to analysis of variance (ANOVA) 
using the general linear model of to establish whether 
significant differences (p<0.05) were present, in which case P 
values for pair-wise differences between groups were 
calculated by Fisher’s least square difference test or 
Satterthwaite approximate F-test of models appropriate for the 
experimental designs. 
 
Results 
Icv dose response effects of L-692,585 and CRH on GH and 
cortisol secretion. 
 After icv administration of 585, plasma GH concentration 
increased in a dose-related manner, with a return to baseline 
by 60 min (Figure 1a and 1b). GH peak response occurred at 
10 min after 3 and 10 μg/kg BW 585 icv injection and at 20 
min after 30 μg/kg BW 585 icv injection. GH concentration 
after icv administration of CRH was similar to the saline 
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control (p>0.05). GH peak concentrations were 4 ± 0.9 ng/ml 
(± SE), 3.5 ± 0.3 ng/ml, 24 ± 9 ng/ml, 35 ± 10 ng/ml, and 50 ± 
9 ng/ml for the saline control, CRH (150 μg) and 585 (3, 10, 
and 30 μg/kg BW doses), respectively. 
 There was no significant difference between dose-
dependent groups in cortisol levels (Figure 1c and 1d). 
Administration of 585 resulted in cortisol levels of similar 
magnitude in all groups compared with saline injected controls 
throughout 140 min. In contrast, cortisol levels abruptly 
increased after CRH icv administration (p<0.05) within 10 
min and remained high compared with saline and 585 treated 
groups. A modest increase to peak cortisol levels occurred at 
10 min after 585 administration with levels returning toward 
baseline by 40 min. Cortisol peak concentrations were 41 ± 8, 
75 ± 9, 52 ± 23, 52 ± 15, and 63 ± 18 ng/ml for the saline 
control, CRH (150 μg), and 585 (3, 10, and 30 μg/kg BW 
doses), respectively. 
 
Interaction of L-692,585 iv and icv injection on GH secretion. 
 In the switchback study, pigs were injected iv or icv with 
saline or 30 μg/kg BW 585 to determine peripheral and central 
action of the GH secretagogue. Average of peak GH response 
to the iv and icv 585 injection was 80 ± 10 ng/ml at 10 min 
and 53 ± 10 ng/ml at 20 min, respectively (Figure 2a). GH 
secretion was attenuated with the increase in numbers of icv 
injection in the switchback study (p<0.05). Peak GH responses 
from the 1
st
 through 4
th
 icv 585 injection were 67 ± 18 ng/ml at 
20 min, 39 ± 22 ng/ml at 10 min, 20 ± 10 ng/ml at 30 min, and 
27 ± 9 ng/ml at 20 min, respectively (Figure 2b). The data also 
showed that the 585 icv injection significantly attenuated the 
response to the 585 iv injection (p<0.001). The average peak 
GH response to iv 585 injection before and after icv 585 
injection was 97 ± 14 and 62 ± 11 ng/ml, respectively (Figure 
2c). In contrast, 585 iv injection did not significantly affect the 
GH response to icv 585 injection (p>0.05). The average peak 
GH response to icv 585 injection before and after iv 585 
injection was 58 ± 17 and 49 ± 10 ng/ml, respectively (Figure 
2d). 
 
SRIF with and without L-692,585 icv injection on GH 
secretion. 
 Peak GH responses following icv administration of 2 or 8 
g/kg SRIF were 3 + 0.6 and 2 + 0.3 ng/ml, respectively, 
which were decreased significantly compared with saline 
alone (4 + 0.9) at 10 min (p<0.05).  GH levels after 2 or 8 
g/kg SRIF treatment continued to drop until 30 min.  Peak 
GH response following 2 or 8 g/kg SRIF + 585 were 31 + 5 
and 31 + 7 ng/ml at 20 min, respectively.  GH response after 
SRIF + 585 was significantly lower than 50 + 9 ng/ml 585 
alone at 20 min (p<0.05, Figure 3a).  There were no 
differences between two different doses (2 or 8 g/kg) of SRIF 
alone or together with 585 in GH response. 
 
 
 
pNPY and pGAL with and without L-692,585 icv injection on 
GH secretion. 
 GH response following icv administration of pNPY was 3 
+ 1 ng/ml, which was similar to saline injection.  pNPY + 585 
increased GH release (25 + 3) at 20 min significantly higher 
(p<0.05) than saline control (Figure 3b).  Peak GH response 
following icv administration of pGAL was 11 + 3 ng/ml at 20 
min and significantly higher than saline control (p<0.05).  
Peak GH response following icv administration of pGAL + 
585 was 42 + 4 ng/ml at 10 min, which was significantly 
higher than pGAL alone and saline control (p<0.05, Figure 
3b).  Peak GH response of 585 alone (50 + 9) was 
significantly higher than pGAL + 585 (36 + 3) at 20 min, but 
the GH response (AUC, ng min
-1
 ml
-1
) was similar (p>0.05) 
following icv administration of pGAL + 585 (876 + 106) and 
585 alone (1284 + 321) (Figure 3b).  pGAL alone increased 
GH release significantly (11 + 3, p<0.05) but pNPY neither 
increased or decreased GH response compared with saline 
control (Figure 3b).  pNPY + 585 increased GH release 
compared with saline control; however, the response was 
less than pGAL + 585 or 585 alone (p<0.05, Figure 3b). 
 
Discussion 
 We describe for the first time in vivo potency of centrally 
administered L-692,585, a more potent nonpeptidyl GH 
secretagogue analogue of L-692,429, in eliciting GH release in 
swine. Transection of the hypophyseal stalk (HST) in the pig 
resulted in a blunted but detectable GH response to 585 iv 
injection. Remarkably, the 2-fold and 16-fold increase in GH 
secretion to 585 and GHRH + 585 respectively in HST 
Yorkshire barrows was similar in magnitude to that seen with 
these treatments in vitro with dispersed pituitary cells. The 
minimal GH response in face of the absence of hypothalamic 
somatostatin (SRIF) tone in the HST animals also indicated 
that inhibition of SRIF tone, in itself, was not adequate to 
induce an intact response. A hypothalamic stimulus also 
seems to be required to elicit a peak GH response to the GH 
secretagogue. 
 The interactions of iv and icv 585 administration and the 
effects of continuous injection in this switchback design 
revealed that the GH response to icv 585 injection was 
delayed and was lower than that following iv-administered 
585.  Attenuated GH responses to the successive icv 585 
injections were clearly illustrated (Figure 2), although the GH 
response to the fourth icv 585 injection was slightly higher 
than that to the 3
rd
 icv 585 treatment, the difference was not 
significant. The GH responses to increasing numbers of iv 585 
injections did not show any sign of attenuation.  These 
findings may suggest different mechanisms of GH-
secretagogue action regulating GH secretion by a direct 
pituitary stimulatory effect when 585 is injected iv, and a 
slower less robust response to icv 585 via GHRH and SRIF 
neurons within the porcine hypothalamus. 
 This switchback design also revealed that there was a 
significant difference in the GH response to iv 585 injection 
before and after icv administered 585. In contrast, 585 iv 
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injection did not influence the GH response to icv injection of 
the secretagogue.  There might be a feedback action to GHRP 
that directly stimulated the brain.  Specific binding sites in rat 
and porcine anterior pituitary membranes and in rat 
hypothalamic membranes with MK0677, another class of GH 
secretagogue. 
 NPY is widely distributed in the mammalian brain and is 
involved in numerous functions including control of feeding, 
growth and reproduction.  Immunohistochemical localization 
of NPY was determined throughout prepubertal development 
in the Meishan pig, a Chinese breed known for its superior 
reproductive characteristics. NPY-like immunoreactivity 
(NPY-IR) in cell bodies and fibers is in many areas of the 
brain at gestational day (g)30, including the basal 
telencephalon, hypothalamus, mesencephalon, pons, and 
medulla.  Throughout prenatal development, cell bodies 
containing NPY-IR generally increase in number and 
distribution in the porcine brain.  The intensity of NPY-IR in 
fibers also increases throughout gestation.  During postnatal 
development the number of cell bodies displaying NPY-IR 
decreases.  The arcuate nucleus (ARC) of the hypothalamus 
shows a dramatic reduction in number of immunoreactive cell 
bodies between postnatal day (pn) 1 (day of birth) and pn 20, 
just before weaning.  Some additional increases in 
immunoreactivity occur postnatally, especially in the 
periventricular hypothalamus and the hippocampus. 
 GAL is a neuropeptide found in the mammalian brain and 
is involved in numerous functions including the control of 
feeding, growth and reproduction.  Immunohistochemical 
localization of GAL was examined throughout prepubertal and 
early postnatal development in the Chinese Meishan pig. 
GAL-like immunoreactivity (GAL-IR) in cell bodies and 
fibers was evident in the brain at g30, primarily in the 
hypothalamus.  Throughout prenatal development, cell bodies 
and fibers containing GAL-IR generally increased in number 
and distribution in the brain.  During postnatal development, 
the number of cell bodies displaying GAL-IR decreased, 
particularly in hypothalamic areas.  Distribution of GAL-IR in 
fibers became more widespread throughout gestational 
development, showing a pattern by pn 1 that continued during 
later postnatal ages (pn 10, 20 and 50). The GAL-IR results 
support the hypothesis that GAL participates in the control of 
feeding, growth and reproduction in the pig. 
 Icv administration of somatostatin (SRIF) decreased 
(p<0.05) GH secretion compared with saline treated controls, 
and decreased (p<0.05) peak GH response when given in 
combination with 585 as compared with 585 treatment alone.  
pGAL modestly increased (p<0.05) GH levels compared with 
saline controls, but when given icv in combination with 585 
peak GH response was lower (p<0.05) compared with 585 
alone.  pNPY administered icv was without effect on GH 
levels compared with saline controls and decreased (p<0.05) 
peak GH response when given in combination with 585 as 
compared with 585 alone.  pNPY exerts a negative influence 
on GH secretion possibly through either stimulating SRIF 
neurons by inhibiting GHRH neurons.  NPY-containing 
neurons have been reported to be located near GHRH neurons 
in the ARC and express GH receptor mRNA. 
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Figure. 1ABCD. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 1.  L-692,585 and CRH icv dose response in male castrate pigs. a GH responses to 585 
administered icv at 0 (saline vehicle), 3, 10, 30 g/kg BW and b CRH at 150 g/kg BW and c Cortisol 
responses to 585 administered icv at 0 (saline vehicle), 3, 10, 30 g/kg BW and d saline vehicle and 
CRH at 150 g/kg BW.  Values for each dose level were means + SE for each time point. 
 
 
a 
b 
c 
d 
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Figure. 2ABCD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 2.  L-692,585 iv and icv total response in male castrate pigs in switchback experiments.  a GH 
responses to 585 administered iv or icv at 30 g/kg BW.  The baseline is saline-treated control.  
Values for each total response were means + SE from 4 injections of 6 animals for each time point.  b 
GH responses to 585 administered iv before icv at 30 g/kg BW.  The baseline is saline-treated 
control.  Values for each iv or icv response were means + SE from two injections for each time point.  
c GH orderly responses to 585 administered iv at 30 g/kg BW.  The baseline is saline-treated control.  
Values for each orderly responses were means + SE from six animals for each time point.  d GH 
responses to 585 administered icv before iv at 30 g/kg BW. The baseline is saline treated control.  
Values for each iv or icv response were means + SE from two injections for each time point. 
a c 
 b  d 
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Figure. 3AB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 3. a GH responses to icv administration of SRIF at 2 and 8 g/kg BW alone and in 
combination with 585 at 30 g/kg BW as compared with saline vehicle and 585 alone.  b GH 
responses to icv administration of pGAL at 4 g/kg BW, pNPY at 4 g/kg BW and in combination 
with 585 at 30 g/kg BW as compared with saline vehicle and 585 alone.  Values are means + SE 
from four and five animals at each time point. 
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